Search

everythinglearnresearchcommunity

for

Search:↓

Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.

Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.

The conversation is about finding a trustworthy and affordable source for RU58841 in Europe, with a comparison between Anagenic and Actifolic. The user seeks experiences from others in the EU to avoid receiving water instead of the product.

The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.

Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

Calecim (PTT-6) Advanced Hair System is a 6-week hair restoration product using stem cell-derived ingredients to stimulate hair growth. Users are skeptical, calling it overpriced and ineffective, suggesting alternatives like LLLT devices or PRP treatments.

The conversation discusses the lack of promising results from the 23rd Annual Meeting of Japan Society of Clinical Hair Restoration, with no significant advancements expected in the next five years. Treatments mentioned include setipiprant, with skepticism about its effectiveness.

CHK-Cu (copper peptide) and C-60 (branched carbon chain) are discussed as potentially more effective than minoxidil for hair regrowth. Some users are skeptical about the claim that DHT isn't the root cause of hair loss, and others are trying these products to see if they work.

The conversation discusses hair loss treatments, with users mentioning dutasteride (Dut) as effective and wishing for more accessible dosages. They also debate the components of the "big 3" treatments, which now include Dut, RU58841, and oral minoxidil, with finasteride and minoxidil being consistently mentioned.

RU58841's legitimacy and sourcing concerns. Users suggest caution and recommend trusted sources over platforms like Amazon.

A user is seeking advice on the efficacy and side effects of homemade topical solutions for hair loss, specifically bicalutamide, estradiol, cyproterone acetate, and spironolactone, as they cannot access RU58841 or pyrilutamide.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

The user saw no significant changes in hair loss after three months on 3mg Dutasteride, having previously used Finasteride and 0.5mg Dutasteride. They plan to continue the high dose for a year despite concerns about side effects and diminishing returns.

User asks about Pyrilutamide release in Europe, specifically Germany, and considers importing it from China. No specific treatments mentioned.

KY19382 is discussed as a potential treatment for creating new hair follicles and possibly curing hair loss. The conversation seeks user experiences and sourcing information for KY19382.

The post and conversation are about a user's 3-month progress using Minoxidil, Finasteride, Nizoral shampoo, and derma-rolling for hair loss. The user reports noticeable improvement in their hairline.

Obtaining treatments for hair loss that are not approved in one's own country, such as pyrilutamide or GT20029. It was suggested to use a middleman to get it, but there is the risk of getting low quality or fake products.

RU58841 caused chest tightness, throat irritation, and headaches, leading the user to stop its use. The user plans to restart with a lower dose if symptoms fully disappear but remains cautious due to anxiety and side effects.

The conversation is about trying PTD-DBM for hair loss treatment. Users are curious about its effectiveness and results.

A user experienced issues with an order from Umbrella Labs, initially not receiving their product, PP405, and facing poor customer service, but eventually received the order after posting about it. Other users also reported similar problems with incomplete orders and lack of communication from the company.

ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.

The conversation is about a person considering participating in a study for Clascoterone, a topical cream for hair loss, and seeking advice on potential side effects. They have mild hair loss and are not currently using other treatments like finasteride.

Choosing between KB and PG solutions for applying RU58841, considering factors like scalp oiliness and absorption. Some users prefer KB for being gentler, while others use PG and recommend washing hair before application for better results.

The conversation is about a user's 3-month hair regrowth progress using finasteride, minoxidil, and a 0.5mm dermaroller, with recent addition of caffeine shampoo. Users are responding positively and inquiring about application methods.

The person is using 1mg of finasteride daily, 2mg of minoxidil, and weekly dermarolling with a 1mm needle. They sometimes use topical minoxidil as well.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.